F/TAF Placebo

DRUG5 trials

Conditions

HIV-1 InfectionHIV-1-infectionPre-Exposure Prophylaxis of HIV-1 Infection

Phase 3

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

CompletedNCT02121795

Gilead SciencesHIV-1 Infection

Start: 2014-05-06End: 2019-03-01Updated: 2020-03-12

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

CompletedNCT02469246

Gilead SciencesHIV-1 Infection

Start: 2015-06-29End: 2019-03-13Updated: 2019-10-25

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

CompletedNCT02607956

Gilead SciencesHIV-1 Infection

Start: 2015-11-11End: 2021-07-05Updated: 2022-03-07

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

Active, not recruitingNCT02842086

Gilead SciencesPre-Exposure Prophylaxis of HIV-1 Infection

Start: 2016-09-02End: 2027-09-30Updated: 2025-11-13

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

CompletedNCT03110380

Gilead SciencesHIV-1-infection

Start: 2017-06-12End: 2021-02-10Updated: 2022-01-11

2025-04-071 citations

Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with <scp>HIV</scp>‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies

HIV Medicine2025-03-21

HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial

2025-02-01

HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo

UNC Libraries2025-01-30

P-512. Changes in Renal Function After Switching from Emtricitabine/Tenofovir Disoproxil Fumarate to Emtricitabine/Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis (PrEP): A Real-World Study

Open Forum Infectious Diseases2025-01-29

P-547. Efficacy and Safety of B/F/TAF in Treatment-Naïve People With HIV Aged ≥ 50 Years: 5-Year Follow-Up From Two Phase 3 Studies

Open Forum Infectious Diseases2025-01-29

P-550. Efficacy and Safety of B/F/TAF in Black Adults with HIV Who Are Treatment Naïve: 5-Year Follow-Up from Two Phase 3 Studies

Open Forum Infectious Diseases2025-01-29

Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy

UNC Libraries2024-12-04

Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy

Journal of Antimicrobial Chemotherapy2024-11-185 citations

Two 5-year studies of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: a plain-language summary

Future Microbiology2024-09-041 citations

2024-07-143 citations

Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy

AIDS2024-02-1311 citations

Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial.

2024-01-3111 citations

HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo

The Journal of Infectious Diseases2023-11-161 citations

Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials.

2023-05-1162 citations

2059. Estimated Background HIV Diagnosis Rates among People Who Could Benefit from Pre-Exposure Prophylaxis (PrEP) at the Metropolitan Statistical Area (MSA) level in the United States, 2012-2019

Open Forum Infectious Diseases2022-12-01

875. Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1 Infected Participants

Open Forum Infectious Diseases2021-11-01

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.

2021-07-0165 citations

Using the adherence‐efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background HIV incidence: a secondary analysis of a randomized, controlled trial

Journal of the International AIDS Society2021-05-0120 citations

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

Clinical Infectious Diseases2020-07-10103 citations

7 more papers not shown

F/TAF Placebo

Sponsors

Conditions

Phase 3

Related Papers